4-Oxa-tricyclo[5.4.2.0^2,6]tridec-12-ene-3,5-dione | 5649-93-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4-Oxa-tricyclo[5.4.2.0^2,6]tridec-12-ene-3,5-dione
• 英文别名: Bicyclo(4.2.2)dec-7-ene-9,10-dicarboxylic anhydride；4-oxatricyclo[5.4.2.02,6]tridec-12-ene-3,5-dione
• CAS: 5649-93-4
• 化学式: C₁₂H₁₄O₃
• 分子量: 206.241
• InChiKey: URCPRWSOPFAFOE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-Oxa-tricyclo[5.4.2.0^2,6]tridec-12-ene-3,5-dione 、 1-(4-aminobutyl)-4-(6-chloro-2-pyrazinyl)-piperazine 在 吡啶 作用下， 生成 2-[4-[4-(6-chloro-2-pyrazinyl)-1-piperazinyl]butyl]octahydro-4,9-etheno-1H-cycloocta[c]pyrrole-1,3-(2H)-dione
  参考文献：
  名称：

  Polycyclic aryl- and heteroarylpiperazinyl imides as 5-HT1A receptor ligands and potential anxiolytic agents: synthesis and structure-activity relationship studies

  摘要：

  A series of polycyclic aryl- and heteroarylpiperazinyl imides were prepared and tested in various receptor-binding and behavioral tests. Parameters measured included in vitro inhibition of D2 and 5-HT1A receptor binding, inhibition of apomorphine (APO) induced stereotyped and climbing behavior, and activity in blocking conditioned avoidance responding (CAR). Several compounds demonstrated moderate to high affinity for the 5-HT1A receptor binding site; compounds 27 and 36 containing the serotonin mimetic (o-methoxyphenyl)piperazinyl moiety and compounds 42 and 50 containing the 2-pyrimidinylpiperazinyl moiety displayed the highest affinity, being equal to that of the 5-HT1A agonist 8-OH-DPAT (Ki = 1-1.3 nM). In addition to affinity at 5-HT1A binding sites, many compounds were active in blocking CAR. Compound 34, 2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]hexahydro-4,7-etheno-1H- cyclobut[f]isoindole-1,3(2H)-dione, demonstrated 3 times the activity of buspirone, blocking CAR in rats with an AB50 of 13 mg/kg. It also displayed high affinity for the 5-HT1A receptor (Ki = 16 nM), which is at least 20 times higher than its affinity for D2 (Ki = 345 nM) and 5-HT2 (Ki = 458 nM) receptors. Compound 34 was selected for further preclinical and pharmacokinetic evaluations for possible development as an anxiolytic agent. Structure-activity relationships within this series are discussed.

  DOI：

  10.1021/jm00402a023

文献信息

• Methods and apparatus for accelerated orthokeratology
  申请人：——

  公开号：US20010016731A1

  公开（公告）日：2001-08-23

  An accelerated method of orthokeratology includes the steps of softening of the cornea with a softening agent, applying a mold to reshape the cornea to a desired anterior curvature, and rapidly restabilizing or “fixing” the corneal tissues so that the cornea retains its new configuration. A chemical softening agent, such as glutaric anhydride is applied to the cornea to soften the cornea, after which a specially designed mold of predetermined curvature and configuration is applied to the cornea. Slight downward pressure is applied to the mold for a predetermined period of time to re-shape the cornea. The mold is maintained in position while a stabilizing agent, such as a UV light source, is positioned above the mold. The stabilizing agent, i.e. UV light, is applied to the cornea for a predetermined time, wherein the stabilizing agent immediately restabilizes the corneal tissue so that the cornea immediately retains its shape upon removal of the mold. The stabilization process can also be used for patients having already undergone traditional orthokeratology to eliminate the need to continue wearing a retainer to maintain the shape of the cornea.

  角膜矫形术的加速方法包括以下步骤：用软化剂软化角膜，使用模具将角膜重塑成所需的前弧度，并迅速重新稳定或 "固定 "角膜组织，使角膜保持新的形态。在角膜上涂抹化学软化剂（如戊二酸酐）以软化角膜，然后在角膜上涂抹专门设计的具有预定弧度和结构的模具。在预定时间内对模具施加轻微的向下压力，以重新塑形角膜。将稳定剂（如紫外线光源）置于模具上方时，模具将保持在原位。将稳定剂（即紫外线）照射到角膜上，持续预定的时间，其中稳定剂会立即重新稳定角膜组织，使角膜在移除模具后立即保持其形状。稳定过程也可用于已接受传统角膜矫形术的患者，使其无需继续佩戴保持器来保持角膜的形状。
• METHODS AND APPARATUS FOR ACCELERATED ORTHOKERATOLOGY
  申请人：Ista Pharmaceuticals, Inc

  公开号：EP1051655B1

  公开（公告）日：2005-09-28
• GLYCOSYLATED LINKER, COMPOUND CONTAINING GLYCOSYLATED LINKER MOIETY AND PHYSIOLOGICALLY ACTIVE SUBSTANCE MOIETY OR SALT THEREOF, AND METHODS FOR PRODUCING SAID U OR SALT THEREOF
  申请人：GLYTECH, INC.

  公开号：US20150299337A1

  公开（公告）日：2015-10-22

  [Problem] The purpose is to provide a compound containing a carrier linker moiety and a physiologically active substance moiety or a salt of the compound, wherein a carrier in the carrier linker moiety is biodegradable and is soluble in water. [Solution] The purpose can be achieved by employing a sugar chain as a carrier and focusing on the structure of a carrier-linker having a specified structure. A compound containing a carrier linker moiety and a physiologically active substance moiety or a salt of the compound is discovered.
• US6161544A
  申请人：——

  公开号：US6161544A

  公开（公告）日：2000-12-19
• US9708413B2
  申请人：——

  公开号：US9708413B2

  公开（公告）日：2017-07-18